Hydroxyethyl Starch versus Albumin in Cardiopulmonary Bypass Prime Solutions

Abstract

To compare hydroxyethyl starch (HES) with 25% albumin, 20 patients undergoing aortocoronary bypass were randomized into two groups: 10 received 1,000 ml of HES and 10 received 200 ml of 25% albumin in a bloodless priming solution for cardiopulmonary bypass (CPB). Platelet aggregation, antithrombin III, reptilase time, fibrinogen, plasminogen, fluid requirements, and hemodynamics were monitored. Platelet aggregation was abnormal in both groups, being relatively poorer in the albumin group. Both groups exhibited below normal antithrombin III and plasminogen levels, with significantly lower antithrombin III levels noted in the HES group postoperatively (41.9 ± 11.8% versus 56.6 ± 9.9%; p = 0.006). Compared with the albumin group, the HES group had slightly, but not significantly, elevated liver function test results, total volume replacement (9,173 ± 2,046 ml versus 8,522 ± 1,192 ml; p = 0.057), packed red blood cell usage (227 ± 284 ml versus 75 ± 168 ml; p = 0.066), and chest tube drainage (599 ± 253 ml versus 454 ± 174 ml; p = 0.144). In the HES group, 5% albumin requirement was greater (386 ± 466 ml versus 50 ± 158 ml; p = 0.002) and percent increase of body weight was higher (5.2 ± 0.8% versus 2.3 ± 0.6%; p = 0.05) postoperatively. Postoperative weight increase and colloid requirements plus trends toward larger blood loss and blood transfusions indicate possible further evaluation. However, results suggest that HES is a safe additive to priming solutions. Compared with albumin, HES has comparable changes in coagulation variables and slightly less severe derangements in platelet aggregation.